U.S. FDA fast-track drug review program stalls after leadership departures
A drug review pilot launched in 2025 to speed approvals for treatments tied to national priorities is no longer advancing new applications at the U.S. Food and Drug Administration. The slowdown follows the departure of former Commissioner Marty Makary and other senior officials, leaving the initiative in limbo despite prior approvals under the scheme.
Highlights
- FDA shelved the Commissioner's National Priority Voucher program after leadership departures, with no new vouchers issued since May and the key executive council inactive.
- Eli Lilly's obesity drug Foundayo received approval nearly 10 months earlier under the pilot, but the program's benefit varied widely and often relied on pre-existing expedited review pathways.
- Regulatory experts and former FDA officials criticized the program for politicizing review decisions, compressing timelines at potential safety risks, and lacking transparency, particularly during June's public hearing.
Program activity slows as oversight structure goes dormant
As first reported by Reuters, the U.S. Food and Drug Administration has shelved the Commissioner's National Priority Voucher program, according to six sources familiar with the matter and internal documents. The initiative, launched in June 2025, aimed to cut drug review timelines to one to two months for therapies addressing urgent national health priorities.Internal documents show no new drugs have received a voucher since Makary left the agency in May, while an executive council of political appointees that played a central role in accelerating reviews has gone dormant. Of the 22 drugs that received a voucher, 12 have been approved, including five since Makary's departure.
A source familiar with the process said companies were told FDA leadership is not moving forward with the program, even though applications remain open. Rich Danker, a former assistant secretary at the Department of Health and Human Services, said the initiative is quietly being phased out and pointed to the departure of its top administrator.
HHS spokesperson Emily Hilliard said the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing to refine its framework. The agency did not respond to requests for comment on the program lead's departure or whether a replacement coordinator has been appointed.
Regulatory impact and criticism of the voucher model
Some companies saw substantial gains from the pilot. Eli Lilly's obesity drug Foundayo was approved nearly 10 months earlier, while several other products moved ahead by eight months or more.Still, the benefit was uneven. For some drugs, the program appears to have shortened reviews by only a few weeks, with approvals relying heavily on existing rapid oncology pathways. Five drugs were approved under the program after Makary left, but three were already deep in review by May and two others depended on pre-existing oncology fast tracks.
Regulatory experts have criticized the pilot for allowing handpicked drugs and for giving political appointees significant influence over review decisions. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, said the program combined the risk of political influence with limited practical benefit because many of the medicines could likely have qualified for other expedited pathways.
Criticism also surfaced during the FDA's June public hearing, when former FDA executive Peter Lurie said the model ceded review decisions to political appointees, risked consumer safety through compressed timelines and lacked transparency. The review of Sanofi's diabetes drug Tzield illustrated those tensions, with former acting drug center director Tracy Beth Hoeg repeatedly raising safety objections between October 2025 and April before agency staff granted accelerated approval in June after she and Makary had left.
As we previously wrote, Nigeria’s regulator intensified oversight by destroying unsafe goods in a NAFDAC crackdown.